FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968408039> ?p ?o ?g. }

• W1968408039 endingPage "914" @default.
• W1968408039 startingPage "909" @default.
• W1968408039 abstract "Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS.We conducted a single-arm, open-label, multicentre phase II study to assess the efficacy and tolerability of panobinostat given orally, 40 mg thrice weekly in patients with advanced pretreated STS. The primary endpoint was the 3-month progression-free rate.Forty-seven STS patients were enrolled between January 2010 and December 2010. Median age was 59 (range 21-79) years, 22 (47%) patients were males. Panobinostat dose was lowered to 20 mg thrice weekly after nine patients were enrolled, based on the recommendation of an independent safety committee. The most common grade 3/4 adverse events were thrombocytopenia, fatigue, lymphopenia and anaemia. Forty-five patients were evaluable for the primary endpoint. Among them, nine patients (20%, 95% CI (10-35%)) were progression-free at 3 months. No partial response was seen, but 17 patients (36%) had stable disease (SD) as their best response. Six patients were progression-free at 6 months.Panobinostat was poorly tolerated at 40 mg thrice a week. Efficacy in unselected advanced STS was limited, although some patients had prolonged SD." @default.
• W1968408039 created "2016-06-24" @default.
• W1968408039 creator A5012736926 @default.
• W1968408039 creator A5022071751 @default.
• W1968408039 creator A5027371764 @default.
• W1968408039 creator A5033615082 @default.
• W1968408039 creator A5038423663 @default.
• W1968408039 creator A5042202815 @default.
• W1968408039 creator A5047920083 @default.
• W1968408039 creator A5048784388 @default.
• W1968408039 creator A5049799682 @default.
• W1968408039 creator A5050746094 @default.
• W1968408039 creator A5052242950 @default.
• W1968408039 creator A5060949051 @default.
• W1968408039 creator A5065856111 @default.
• W1968408039 creator A5073713547 @default.
• W1968408039 creator A5076354847 @default.
• W1968408039 creator A5085936617 @default.
• W1968408039 date "2013-08-01" @default.
• W1968408039 modified "2023-10-11" @default.
• W1968408039 title "A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group" @default.
• W1968408039 cites W1828438395 @default.
• W1968408039 cites W1967018540 @default.
• W1968408039 cites W1970421873 @default.
• W1968408039 cites W1972805469 @default.
• W1968408039 cites W2003600960 @default.
• W1968408039 cites W2017607635 @default.
• W1968408039 cites W2018826865 @default.
• W1968408039 cites W2023351948 @default.
• W1968408039 cites W2025847887 @default.
• W1968408039 cites W2053022025 @default.
• W1968408039 cites W2057195209 @default.
• W1968408039 cites W2062040583 @default.
• W1968408039 cites W2072237399 @default.
• W1968408039 cites W2092784915 @default.
• W1968408039 cites W2093507272 @default.
• W1968408039 cites W2100972878 @default.
• W1968408039 cites W2114033240 @default.
• W1968408039 cites W2129563393 @default.
• W1968408039 cites W2132456669 @default.
• W1968408039 cites W2149099455 @default.
• W1968408039 cites W2168713493 @default.
• W1968408039 cites W2170806279 @default.
• W1968408039 cites W2258225306 @default.
• W1968408039 cites W2559894657 @default.
• W1968408039 doi "https://doi.org/10.1038/bjc.2013.442" @default.
• W1968408039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3749588" @default.
• W1968408039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23922114" @default.
• W1968408039 hasPublicationYear "2013" @default.
• W1968408039 type Work @default.
• W1968408039 sameAs 1968408039 @default.
• W1968408039 citedByCount "53" @default.
• W1968408039 countsByYear W19684080392014 @default.
• W1968408039 countsByYear W19684080392015 @default.
• W1968408039 countsByYear W19684080392016 @default.
• W1968408039 countsByYear W19684080392017 @default.
• W1968408039 countsByYear W19684080392018 @default.
• W1968408039 countsByYear W19684080392019 @default.
• W1968408039 countsByYear W19684080392020 @default.
• W1968408039 countsByYear W19684080392021 @default.
• W1968408039 countsByYear W19684080392022 @default.
• W1968408039 countsByYear W19684080392023 @default.
• W1968408039 crossrefType "journal-article" @default.
• W1968408039 hasAuthorship W1968408039A5012736926 @default.
• W1968408039 hasAuthorship W1968408039A5022071751 @default.
• W1968408039 hasAuthorship W1968408039A5027371764 @default.
• W1968408039 hasAuthorship W1968408039A5033615082 @default.
• W1968408039 hasAuthorship W1968408039A5038423663 @default.
• W1968408039 hasAuthorship W1968408039A5042202815 @default.
• W1968408039 hasAuthorship W1968408039A5047920083 @default.
• W1968408039 hasAuthorship W1968408039A5048784388 @default.
• W1968408039 hasAuthorship W1968408039A5049799682 @default.
• W1968408039 hasAuthorship W1968408039A5050746094 @default.
• W1968408039 hasAuthorship W1968408039A5052242950 @default.
• W1968408039 hasAuthorship W1968408039A5060949051 @default.
• W1968408039 hasAuthorship W1968408039A5065856111 @default.
• W1968408039 hasAuthorship W1968408039A5073713547 @default.
• W1968408039 hasAuthorship W1968408039A5076354847 @default.
• W1968408039 hasAuthorship W1968408039A5085936617 @default.
• W1968408039 hasBestOaLocation W19684080391 @default.
• W1968408039 hasConcept C104317684 @default.
• W1968408039 hasConcept C126322002 @default.
• W1968408039 hasConcept C136948725 @default.
• W1968408039 hasConcept C141071460 @default.
• W1968408039 hasConcept C142724271 @default.
• W1968408039 hasConcept C143998085 @default.
• W1968408039 hasConcept C185592680 @default.
• W1968408039 hasConcept C197934379 @default.
• W1968408039 hasConcept C203092338 @default.
• W1968408039 hasConcept C2776694085 @default.
• W1968408039 hasConcept C2778256501 @default.
• W1968408039 hasConcept C2778305200 @default.
• W1968408039 hasConcept C2778375690 @default.
• W1968408039 hasConcept C2778629024 @default.
• W1968408039 hasConcept C2780225316 @default.
• W1968408039 hasConcept C2780739268 @default.
• W1968408039 hasConcept C31760486 @default.
• W1968408039 hasConcept C535046627 @default.

• next